Abstract:Importance: Approximately 1% to 3% of gastric cancers and 5% of lobular breast cancers are hereditary. Loss of function CDH1 gene variants are the most common gene variants associated with hereditary diffuse gastric cancer and lobular breast cancer. Previously, the lifetime risk of gastric cancer was estimated to be approximately 25% to 83% and for breast cancer it was estimated to be approximately 39% to 55% in individuals with loss of function CDH1 gene variants. Objective: To describe gastric and breast cancer risk estimates for individuals with CDH1 variants. Design, setting, and participants: Multicenter, retrospective cohort and modeling study of 213 families from North America with a CDH1 pathogenic or likely pathogenic (P/LP) variant in 1 or more family members conducted between January 2021 and August 2022. Main outcomes and measures: Hazard ratios (HRs), defined as risk in variant carriers relative to noncarriers, were estimated for each cancer type and used to calculate cumulative risks and risks per decade of life up to age 80 years. Results: A total of 7323 individuals from 213 families were studied, including 883 with a CDH1 P/LP variant (median proband age, 53 years [IQR, 42-62]; 4% Asian; 4% Hispanic; 85% non-Hispanic White; 50% female). In individuals with a CDH1 P/LP variant, the prevalence of gastric cancer was 13.9% (123/883) and the prevalence of breast cancer among female carriers was 26.3% (144/547). The estimated HR for advanced gastric cancer was 33.5 (95% CI, 9.8-112) at age 30 years and 3.5 (95% CI, 0.4-30.3) at age 70 years. The lifetime cumulative risk of advanced gastric cancer in male and female carriers was 10.3% (95% CI, 6%-23.6%) and 6.5% (95% CI, 3.8%-15.1%), respectively. Gastric cancer risk estimates based on family history indicated that a carrier with 3 affected first-degree relatives had a penetrance of approximately 38% (95% CI, 25%-64%). The HR for breast cancer among female carriers was 5.7 (95% CI, 2.5-13.2) at age 30 years and 3.9 (95% CI, 1.1-13.7) at age 70 years. The lifetime cumulative risk of breast cancer among female carriers was 36.8% (95% CI, 25.7%-62.9%). Conclusions and relevance: Among families from North America with germline CDH1 P/LP variants, the cumulative risk of gastric cancer was 7% to 10%, which was lower than previously described, and the cumulative risk of breast cancer among female carriers was 37%, which was similar to prior estimates. These findings inform current management of individuals with germline CDH1 variants.

Managing CDH1 Cancer Risks in a Child: Complex Decision Making in a Family With Hereditary Diffuse Gastric Cancer

Therapeutic and prophylactic gastrectomy in a family with hereditary diffuse gastric cancer secondary to a CDH1 mutation: a case series

S5154 Management Considerations in a Patient With a CDH1 Pathogenic Variant With a History of Roux-en-Y Gastric Bypass Surgery

Clinical approach for managing patients with unexpected CDH1 mutations: A case report

Points to consider regarding prophylactic total gastrectomy in germline CDH1 variant carriers

CDH1 variants leading to gastric cancer risk management decision‐making experiences in emerging adults: ‘I am not ready yet’

Laparoscopic Prophylactic Total Gastrectomy for Hereditary Diffuse Gastric Cancer in CDH1 Mutation Carriers

Current advances and challenges in Managing Hereditary Diffuse Gastric Cancer (HDGC): a narrative review

S5022 Prophylactic Total Gastrectomy in an Asymptomatic 27-Year-Old School Teacher with Genetic Gastric Cancer Syndrome

Germline CDH1 Variants and Lifetime Cancer Risk

Combined loss of CDH1 and downstream regulatory sequences drive early-onset diffuse gastric cancer and increase penetrance of hereditary diffuse gastric cancer

Germline Mutational Analysis of CDH1 and Pathologic Features in Familial Cancer Syndrome with Diffuse Gastric Cancer/breast Cancer Proband in a Chinese Family.

Overview on New Progress of Hereditary Diffuse Gastric Cancer Withcdh1variants

Progress in Diagnosis and Treatment of Hereditary Diffuse Gastric Cancer

Germline mutations in hereditary diffuse gastric cancer

Endoscopic screening for identification of signet ring cell gastric cancer foci in carriers of germline pathogenic variants in CDH1

Laparoscopic prophylactic total gastrectomy with linear stapler side-to-side esophagojejunal anastomosis for hereditary diffuse gastric cancer syndrome in 2 siblings.

Current advances in understanding the molecular profile of hereditary diffuse gastric cancer and its clinical implications

Association of CDH1 Germline Variants and Colon Polyp Phenotypes in Patients with Hereditary Diffuse Gastric Cancer

Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis

Transcriptomic Profiling and Quantitative High-Throughput (qhts) Drug Screening of CDH1 Deficient Hereditary Diffuse Gastric Cancer (HDGC) Cells Identify Treatment Leads for Familial Gastric Cancer